News-Archiv

Annual Report 2022

Bern led international study will reduce overtherapy in appendiceal NET

Evidence leads to improved patient treatment! An international study led by endocrine surgery of the Inselspital and our Institute challanges a dogma: Contrary to the current concept seem microscopic lymph node metastases of appendiceal NET irrelevant for patients. Therefore there is no indication for right sided hemicolectomy.

Renewal of the accreditation as testing laboratory for pathological diagnostics

We are glad to announce the renewal of the accreditation. Starting 29.11.2022 our institute is accredited by the Swiss Accreditation Service (SAS) according to the standard ISO 15189:2012 and the Swiss standard SN EN ISO 15189:2013 as a medical laboratory for pathological diagnostics. Thank you for your trust and cooperation!

Tumour Center Bern: 5 years of successful UCI partnership

The Institute of Tissue Medicine and Pathology of the University of Bern proudly celebrates five years of partnership with the Tumor Center Bern, the University Cancer Center Inselspital (UCI). Our collaboration with experts from various disciplines contributes to the recognition of the UCI as a leading cancer centre. A central aspect of our work is participation in interdisciplinary tumour boards, where experts create individual treatment plans to ensure optimal therapy and diagnosis for each patient. We look forward to continuing this important work and actively participating in the latest developments in cancer medicine. The Institute of Tissue Medicine and Pathology of the University of Bern proudly celebrates five years of partnership with the Tumor Center Bern, the University Cancer Center Inselspital (UCI). Our collaboration with experts from various disciplines contributes to the recognition of the UCI as a leading cancer centre. A central aspect of our work is participation in interdisciplinary tumour boards, where experts create individual treatment plans to ensure optimal therapy and diagnosis for each patient. We look forward to continuing this important work and actively participating in the latest developments in cancer medicine.

With a hydrogel against black skin cancer

Researchers at the University of Bern have developed a therapy option that activates the body's own defense system against black skin cancer. Components of a bacterium are embedded in gel and applied directly to the area of the tumor. In the model, the gel was shown to reduce tumor growth, inhibit its spread to other organs and thereby prolong survival. In a next step, the gel will be tested for its efficacy in patients in clinical trials..

Bernese Innovation for the Pathology of the Future

Alessandro Lugli and Miryam Blassnigg from the Institute of Pathology at the University of Bern have developed a medical cockpit, called the Pathojet, which is the first of its kind in the world. In an interview, they explain the advantages the device offers for their field and their patients. Link for the Movie and Interview:

Teacher of the Year 2021

Since the past year was a special one and each medical school year underwent its own particular challenges, every class had the chance to choose a “Teacher of the Year”. We warmly congratulate Y. Banz, selected for Year 4.

SwissMedTalk

What does a pathologisch do all Day long? What does pathology offer ans does the future of Pathology Look like? Questions and answers - a project by Willi Balandies and Afreed Ashraf - SwissMedTalk

Napoleon’s Death Cause of

Contribution on RTSI for the Bicentenary of Napoleon’s Death on St. Helena, May 5th 1821

Tumour budding in solid cancers

Our colorectal Cancer (CRC) research group organized in 2016 the "International Tumour Budding Consensus Conference (ITBCC)" which led to the implementation of tumour budding in the TNM/WHO classifications and in the NCCN (National Comprehensive Cancer Network), CAP (College of American Pathologists) and ESMO (European Society for Medical Oncology) guidelines as well. Our recent review published in Nature Reviews Clinical Oncology not only summarizes the clinical scenarios of tumour budding in CRC and other solid cancers, but also focuses on the molecular and biological aspects and the association with EMT (epithelial-mesenchymal transition) and TME (tumour microenvironment). Key processes involved in the tumour budding phenotype (from Lugli et al, Nat Rew Clin Oncol 2020).

Increasing the effectiveness of immunotherapy against skin cancer

Researchers at the University of Bern have discovered a mechanism in the body’s own immune system which is responsible for the maturation and activation of immune cells. In the fight against skin cancer, the results have the potential to help immunotherapies succeed, even in patients for whom they have so far been ineffective.

The IFP is visible on Nature Index 2019!